Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
TOBRADEX is a fixed-dose ophthalmic suspension combining tobramycin (aminoglycoside antibiotic) and dexamethasone (corticosteroid) for topical eye use. It treats bacterial ocular infections with inflammatory components by simultaneously eliminating bacteria and reducing inflammation. The combination addresses both infection and immune response in external eye disease.
This 35-year-old product is entering loss-of-exclusivity phase, signaling potential downsizing of commercial teams and transition toward generic defense strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
Zylet vs TobraDex in Blepharokeratoconjunctivitis
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle
A Clinical Study of Tobradex AF
Worked on TOBRADEX at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TOBRADEX offers stable, established pharmaceutical experience in ophthalmology but limited growth upside as the product approaches LOE. Career advancement requires expertise in defensive strategies, generic competition management, and operational efficiency rather than innovation or market expansion.